An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Jardiance

Chemical Nameempagliflozin
Dosage FormTablets (oral; 10mg, 25mg)
Drug ClassInhibitors
SystemEndocrine, Cardiovascular
CompanyBoehringer Ingelheim Pharmaceuticals
Approval Year2014

Indication

  • An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Jardiance (empagliflozin) Prescribing Information2014Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Document TitleYearSource
Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.2017NIHR
Clinical review report: empagliflozin (jardiance).2016CADTH
Pharmacoeconomic report: empagliflozin (jardiance).2016CADTH
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes.2016NICE
Document TitleYearSource
Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis.2021IJC Heart and Vasculature
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: A systematic review and network meta-analysis. 2020Annals of Internal Medicine
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. 2020The Lancet Diabetes and Endocrinology
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map. 2020The Lancet Diabetes and Endocrinology
Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis.2020PLoS One
Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: A systematic review and meta-analysis.2020Medical Sciences
Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: A systematic review and meta-analysis.2020Medicine
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.2019PLoS Medicine
Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. 2019Diabetes Research and Clinical Practice
Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons.2018Diabetes Therapy
Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials.2018Medicine
SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis. 2018Diabetes Obesity and Metabolism
Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis.2018Saudi Journal of Biological Sciences
Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials.2018CMAJ Open
Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. 2018Diabetes and Metabolism
SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.2017Diabetologia
Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus. 2017Diabetes Research and Clinical Practice
Sodium–glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.2017Diabetes Obesity and Metabolism
Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus.2016The American Journal of Cardiology
Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and meta-analysis.2016PLoS One
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.2016Diabetes Obesity and Metabolism
Document TitleYearSource
Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus.2020Diabetology & Metabolic Syndrome